UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Diabetes, obesity & metabolism, 2014-04, Vol.16 (4), p.366-375

2014

Volltextzugriff (PDF)

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

Diabetic medicine, 2016-04, Vol.33 (4), p.471-477

2016

Volltextzugriff (PDF)

What is innovation in the area of medicines? The example of insulin and diabetes

Diabetic medicine, 2019-12, Vol.36 (12), p.1528-1529

2019

Volltextzugriff (PDF)

Development and validation of a cost-utility model for Type 1 diabetes mellitus

Diabetic medicine, 2015-08, Vol.32 (8), p.1023-1035

2015

Volltextzugriff (PDF)

Diminishing Marginal Disutility of Hypoglycaemic Events

Value in health, 2013-11, Vol.16 (7), p.A445-A445

2013

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

Benchmarks for interpretation of score differences on the SF-36 health survey

Value in health, 2013-05, Vol.16 (3), p.A35-A35

2013

Volltextzugriff (PDF)

PDB19 A Systematic Review of Recent Data Describing the Risk of Complications in Type 1 Diabetes Mellitus Patients

Value in health, 2012-11, Vol.15 (7), p.A496-A497

2012

Volltextzugriff (PDF)

PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

Value in health, 2019-11, Vol.22, p.S583-S583

2019

Volltextzugriff (PDF)

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease

Alzheimer's research & therapy, 2024-02, Vol.16 (1), p.48-11, Article 48

2024

Volltextzugriff (PDF)

PDB27 - Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Value in health, 2017-10, Vol.20 (9), p.A478-A479

2017

Volltextzugriff (PDF)

Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Value in health, 2017-10, Vol.20 (9), p.A478-A479

2017

Volltextzugriff (PDF)

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

Current medical research and opinion, 2017-04, Vol.33 (4), p.647-655

2017

Volltextzugriff (PDF)

PDB48 - Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Value in health, 2016-11, Vol.19 (7), p.A673-A673

2016

Volltextzugriff (PDF)

Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Value in health, 2016-11, Vol.19 (7), p.A673-A673

2016

Volltextzugriff (PDF)

Income-related inequality in utilization of health services in Denmark: Evidence from Funen County

Scandinavian journal of public health, 2006-10, Vol.34 (5), p.462-471

GUNDGAARD, JENS

2006

Volltextzugriff (PDF)

PDB43 - Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Value in health, 2016-11, Vol.19 (7), p.A672-A672

2016

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Value in health, 2016-11, Vol.19 (7), p.A672-A672

2016

Volltextzugriff (PDF)

Income related inequality in prescription drugs in Denmark

Pharmacoepidemiology and drug safety, 2005-05, Vol.14 (5), p.307-317

Gundgaard, Jens

2005

Volltextzugriff (PDF)

PDB81 - Diminishing Marginal Disutility of Hypoglycaemic Events

Value in health, 2013-11, Vol.16 (7), p.A445-A445

2013

Volltextzugriff (PDF)

PDB65 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

PDB64 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

PRM126 - Benchmarks for interpretation of score differences on the SF-36 health survey

Value in health, 2013-05, Vol.16 (3), p.A35-A35

2013

Volltextzugriff (PDF)

Use of six main drug therapeutic groups across educational groups: self-reported survey and prescription records

Journal of clinical pharmacy and therapeutics, 2005-06, Vol.30 (3), p.259-269

2005

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieDiabetes Therapy

Zeitschrift / SerieJournal Of Medical Economics

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)

Sprache

Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(12)
Adult
(9)
Diabetes
(8)
Female
(8)
Internal Medicine
(8)
Male
(8)
Hypoglycemia
(6)
Middle Aged
(6)
Public, Environmental & Occupational Health
(6)
Insulin
(5)
Patients
(5)
Cost-Benefit Analysis
(4)
Health Care Costs
(4)
Health Economics
(4)
Hypoglycemic Agents - Economics
(4)
Medical Research
(4)
Adolescent
(3)
Aged
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

What is innovation in the area of medicines? The example of insulin and diabetes

Development and validation of a cost-utility model for Type 1 diabetes mellitus

Diminishing Marginal Disutility of Hypoglycaemic Events

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Benchmarks for interpretation of score differences on the SF-36 health survey

PDB19 A Systematic Review of Recent Data Describing the Risk of Complications in Type 1 Diabetes Mellitus Patients

PDB60 COST-EFFECTIVENESS OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U300 IN THE NETHERLANDS: EVIDENCE FROM A RANDOMISED CONTROLLED TRIAL (RCT)

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease

PDB27 - Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

PDB48 - Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Annual Cost and Effects of Switching to Insulin Degludec from Other Basal Insulins: Evidence from Swedish Real-World Data

Income-related inequality in utilization of health services in Denmark: Evidence from Funen County

PDB43 - Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Cost-Effectiveness of Insulin Degludec/Insulin Aspart (IDEGASP) Compared with Biphasic Insulin Aspart (BIASP 30) in Patients with Type 2 Diabetes Mellitus from a Mexican Healthcare Perspective

Income related inequality in prescription drugs in Denmark

PDB81 - Diminishing Marginal Disutility of Hypoglycaemic Events

PDB65 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

PDB64 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

PRM126 - Benchmarks for interpretation of score differences on the SF-36 health survey

Use of six main drug therapeutic groups across educational groups: self-reported survey and prescription records

Aktive Filter

Suchergebnisse filtern